ClinicalTrials.gg
RecruitingNCT06799052Updated Jun 30, 2026

Cervical Preparation for Same-Day Dilation & Evacuation

An interventional study of Transcervical single-balloon catheter and Synthetic osmotic dilators in Abortion, Second Trimester, Procedural Pain and Procedural Complication, sponsored by Boston Medical Center. Recruiting at 1 site in United States. Open to female participants aged 16 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Boston Medical Center · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
16 Years and older
Sex
Female
01

Study summary

This is a noninferiority randomized control trial of two cervical preparation methods prior to same-day Dilation \& Evacuation (D\&E). Cervical preparation is a process that softens and dilates the cervix prior to a procedure.

The primary objective is to evidence noninferiority of cervical preparation using a single-balloon catheter method when compared to a group receiving osmotic dilators, specifically in D\&E operative time.

Secondary objectives will compare the two methods for adequate dilation, ability to complete the operation in the same day, participant pain, satisfaction and safety.

02

Conditions studied

  • Abortion, Second Trimester
  • Procedural Pain
  • Procedural Complication

Keywords

  • Cervical Dilation and Evacuation (D&E)
  • Transcervical single-balloon catheter
  • Osmotic dilators
  • Adequate dilation
  • Patient satisfaction
03

In context

Pain, Procedural

241 studies on the registry are indexed under Pain, Procedural; 64 are open to participants now.

This study's planned enrollment of 32 is below the median of 90 across 227 interventional studies indexed under Pain, Procedural.

Browse Pain, Procedural studies →

Lead sponsor

Boston Medical Center is the lead sponsor of 323 studies on the registry; 33 are open to participants now.

Of its 34 completed or terminated interventional studies of FDA-regulated products, 28 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between 16 weeks 0 days - 18 weeks 6 days gestational age who are pursuing termination, based on reliable gestational age (defined as ultrasonography performed by a clinical provider, or a certain last menstrual period)
  • Able to provide
  • English- or Spanish-speaking
  • Singleton intrauterine pregnancy

Exclusion criteria

Exclusion Criteria:

  • Allergy to betadine, aquacryl hydrogel, latex-free silicone single-balloon catheter, synthetic or natural osmotic dilators
  • Fetal demise or known fetal anomaly
  • >45
  • Incarceration or other inability to give
  • Decide to undergo cervical preparation overnight prior to next-day D\&E
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Transcervical single-balloon catheter group

    Participants randomized to this arm will have cervical dilation done using a transcervical single-balloon catheter.

    Device: Transcervical single-balloon catheter

  • Active comparator
    Osmotic dilators group

    Participants randomized to this arm will have cervical dilation done using osmotic dilators.

    Device: Synthetic osmotic dilators

Interventions

  • DeviceTranscervical single-balloon catheter

    A single-balloon (Foley) catheter will be placed through the cervix and filled to 30cc of water or saline. The balloon will remain in the participant until their procedure, usually 3-4 hours, or earlier if it falls out on its own.

    Also known as: Foley catheter

  • DeviceSynthetic osmotic dilators

    Dilators will be maintained in the cervix between 3-4 hours, during which each dilator rod will swell several times its initial dried diameter.

    Also known as: Dilapan-S, seaweed laminaria

06

What researchers measure

Primary outcomes

  1. Dilation & Evacuation (D&E) Operative time

    the total duration in D\&E operative time measured in minutes. Operative start time will be marked as the time that the speculum is inserted for the first time. Operative end time will be marked as the time that the speculum is removed at the end of the case.

    Time frame: at end of procedure about 20 minutes

Secondary outcomes

  1. Participant preoperative pain

    Participant pain will be assessed via a 100 point visual analog scale immediately post-cervical preparation and at every hour interval until their D\&E. Higher scores are associated with more pain.

    Time frame: every hour until procedure, on average 3 hours

  2. Participant satisfaction

    Participant satisfaction will be assessed with a 5-point Likert scale from very dissatisfied to very satisfied.

    Time frame: after dilation, on average 3 hours

  3. Cervical dilation

    Cervical dilation will be measured in millimeters at the beginning of the procedure by the surgeon.

    Time frame: beginning of procedure, on average 3 hours

  4. Number of participants with adequate cervical dilation

    Abstracted from the operative record, dilation will be considered adequate if no manual dilation is needed.

    Time frame: beginning of procedure, on average 3 hours

  5. Number of participants with surgery completed in the same day

    Abstracted from the electronic medical record, whether the surgery was completed in the same day as the dilation will be recorded as yes or no.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.

Of 141 non-industry interventional studies with no phase under Pain, Procedural, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 15. This study's planned 18 months is above that.

Counting every sponsor, half of 141 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2025
First posted
Jan 29, 2025
StartActual
Jun 12, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06799052
Responsible party
Sponsor
First posted
Jan 29, 2025
Start date
Jun 12, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jun 30, 2026

Study contacts

Anjanique Mariquit Lu, MD
Contact
anjaniquemariquit.lu@bmc.org
617 414 5716
Alana Martinusen, MPH
Contact
alana.martinusen@bmc.org
617 383 3500
Anjanique Mariquit Lu, MD
principal investigator · Boston Medical Center, Obstetrics and Gynecology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion